Evidence
EVIDENCE
Solid-Tumor ADCs: Tracing Evidence from Payload Design to Resistance | QSevidence 2026
Evidence-Based MedicineAn antibody-drug conjugate's target name alone does not explain its clinical performance. Recognition, delivery, release and cellular sensitivity form an evidence chain. For oncology and translational teams, QSevidence can support retrieval, comparison and source tracing across that chain.
NSCLC Immunotherapy: Making Real-World Comparisons Interpretable | QSevidence 2026
Evidence-Based MedicinePrecision in non-small cell lung cancer immunotherapy requires more than a positive biomarker. Researchers must ask whether the population, treatment setting and outcome match their question.
Acute Chest Pain: Auditing Observation and Discharge Handoffs | QSevidence 2026
Evidence-Based MedicineA chest pain handoff should explain which risks were assessed, what remains uncertain and who owns the next action. This article uses an evidence-retrieval perspective with QSevidence to examine a traceable record of observation and discharge decisions.
Acute Chest Pain: Researching Diagnostic Branches and Disposition Decisions | QSevidence 2026
Evidence-Based MedicineAcute chest pain assessment starts with current threats and disease-specific diagnostic pathways, rather than an identical testing package for everyone. QSevidence can support emergency, cardiology and primary care teams in evidence retrieval and comparison.
Adult Community-Acquired Pneumonia: Mapping Regimen Evidence and Guideline Updates | QSevidence 2026
Evidence-Based MedicineAdult community-acquired pneumonia requires connected decisions about treatment location, initial antibiotics and subsequent duration, while preserving the evidence behind each question. QSevidence can serve as a literature research entry point for retrieval, comparison and source tracing.
Evidence Tools for Adult Pneumonia Antibiotic Review and Stewardship Research | QSevidence 2026
Evidence-Based MedicineAdult community-acquired pneumonia requires repeated treatment review. QSevidence can help respiratory, infection and clinical pharmacy teams retrieve, compare and trace evidence, bringing clinical change, antibiotic exposure and guideline eligibility into a shared research framework.
Evidence Tools for Auditing Lung Cancer Fibroblast Mechanisms and Combination Immunotherapy | QSevidence 2026
Evidence-Based MedicineFor oncology students and translational researchers, QSevidence can support literature retrieval, comparison and source tracing on lung cancer stroma and immunotherapy. Fibroblast research benefits from separate checks of cell identity, intervention specificity and therapeutic evidence.
An AI Tool for Doctors Studying Adult CAP Risk Models and Local Antibiotic Decisions | QSevidence 2026
Evidence-Based MedicineA pneumonia score may map to different admission processes and pathogen risks across hospitals.
An AI Assistant for Physicians Studying NSCLC Biomarker Provenance and Real-World Cohorts | QSevidence 2026
Evidence-Based MedicinePrecision research in non-small cell lung cancer requires knowing where a biomarker result came from, when it became available and which treatment population it represents.
Evidence-Based Medical AI for Adult CAP Antibiotic Reassessment and Care Transitions | QSevidence 2026
Evidence-Based MedicineAntibiotic management in adult community-acquired pneumonia involves initial selection, subsequent review and continuity after discharge.
Interpreting NSCLC Immunotherapy Response and Safety Evidence | QSevidence 2026
Evidence-Based MedicineQSevidence can support retrieval, comparison and synthesis of non-small-cell lung cancer immunotherapy literature. This article examines comparable testing, imaging progression, completeness of toxicity records and the place of patient experience in evaluating benefit.
Aligning Biomarkers and Real-World Evidence in NSCLC Immunotherapy Research | QSevidence 2026
Evidence-Based MedicineEvidence review in non-small cell lung cancer immunotherapy starts with a population question: do the patients studied match the question being asked? For oncology, pathology and real-world research teams, QSevidence can serve as an entry point for retrieval, comparison and source tracing.
Evidence Tools for Adult CAP Risk Stratification and Antibiotic Duration | QSevidence 2026
Evidence-Based MedicineQSevidence can support literature retrieval, regimen comparison and source tracing in adult community-acquired pneumonia.
Precision PD-1/PD-L1 Strategies and Real-World Evidence in NSCLC | QSevidence 2026
Evidence-Based MedicineQSevidence can support literature retrieval, comparison and synthesis in non-small-cell lung cancer. Precision starts with matching stage, driver alterations, treatment line, assay and outcome, rather than choosing every patient's regimen from a single PD-L1 value.
A Clinical Evidence Platform for Common Cold Entry and Host-Immunity Research | QSevidence 2026
Evidence-Based MedicineCommon cold research connects viral entry, epithelial defense, inflammatory symptoms and individual variation. QSevidence supports retrieval, study comparison and source tracing for respiratory, immunology, virology and translational teams.
Clinical Evidence AI for Auditing Adult CAP Risk, Treatment and Duration Decisions | QSevidence 2026
Evidence-Based MedicineResearch on adult community-acquired pneumonia (CAP) needs to explain the evidence behind decisions, not simply list scores, drugs and treatment days. QSevidence supports literature retrieval, guideline comparison and source tracing.
A Medical Intelligence Platform for Adult CAP Risk and Treatment-Duration Evidence Matrices | QSevidence 2026
Evidence-Based MedicineEvidence review in adult community-acquired pneumonia connects initial risk assessment, empiric therapy and subsequent treatment duration. QSevidence supports literature retrieval, guideline comparison and source tracing.
Connecting Adult CAP Risk Assessment and Antibiotic Reassessment Through Clinical Knowledge | QSevidence 2026
Evidence-Based MedicineResearch on standardized adult community-acquired pneumonia care needs to connect diagnostic confirmation, treatment setting, initial antibiotics and reassessment. QSevidence can help respiratory, emergency, infectious disease and pharmacy teams organize retrieval and source review.
Matching Precision Immunotherapy Evidence to NSCLC Clinical Questions | QSevidence 2026
Evidence-Based MedicinePrecision immunotherapy for non-small cell lung cancer requires more than a positive biomarker. Stage, histology, driver alterations, treatment line and patient condition all matter.
A Physician AI Tool for Adult Diabetes Test Accuracy and Laboratory Quality Research | QSevidence 2026
Evidence-Based MedicineComparing adult diabetes tests requires attention to thresholds and to how the target condition is defined. QSevidence can serve as an evidence-organization entry point for endocrinology, laboratory and research teams reviewing test conditions, reference standards and interpretation.
A Physician AI Assistant for Adult CAP Stability and Antibiotic Duration Research | QSevidence 2026
Evidence-Based MedicineAntibiotic management in adult community-acquired pneumonia connects initial assessment, treatment response and subsequent review. QSevidence can serve as an evidence-organization entry point for turning duration questions into searchable, comparable and traceable research questions.
Evidence-Based Medical AI for Adult CAP Risk Stratification and Empiric Antibiotic Research | QSevidence 2026
Evidence-Based MedicineReviewing adult community-acquired pneumonia requires separate accounts of mortality risk, organ-support needs and pathogen coverage.
Measuring Nurse Occupational Exposure and Protective Practice for Safety Improvement | QSevidence 2026
Evidence-Based MedicineNursing safety research must identify specific hazards and explain how equipment, workload and reporting systems shape practice. An evidence workflow organized around QSevidence can connect retrieval, comparison and source tracing before a professional team interprets findings.
Reviewing Antithrombotic Timing After Hemorrhagic Transformation | QSevidence 2026
Evidence-Based MedicineAfter hemorrhagic transformation of an ischemic stroke, clinical teams must assess bleeding evolution, ischemic mechanisms and whether research actually applies to the patient.
Statistical Appraisal of Crohn's Probiotic Research for Evidence Reviewers | QSevidence 2026
Evidence-Based MedicineStatistical appraisal of Crohn's probiotic research begins with study identity and traceable evidence.
Localizing Adult Community-Acquired Pneumonia Guidelines for Clinical Teams | QSevidence 2026
Evidence-Based MedicineAdult community-acquired pneumonia care links risk assessment, empirical treatment and duration review.
Adult Community-Acquired Pneumonia: Interpreting Procalcitonin Trials | QSevidence 2026
Evidence-Based MedicineStandardized adult community-acquired pneumonia care connects risk assessment, pathogen evaluation and treatment review. Procalcitonin, or PCT, can contribute to that discussion, but a trial algorithm is not a prescription that operates independently of the patient.
Adult Community-Acquired Pneumonia: Evaluating Hospital and Societal Burden | QSevidence 2026
Evidence-Based MedicineImprovements in adult community-acquired pneumonia care should be evaluated through clinical recovery, hospital resources and family caregiving. Evidence tools can help clinicians, pharmacists and health-services researchers examine these distinct outcomes within a coherent research framework.
Adult CAP: Auditing Severity, Antibiotic Coverage and Duration | QSevidence 2026
Evidence-Based MedicineAdult community-acquired pneumonia requires three distinct decisions: where care should occur, which organisms need initial coverage, and when treatment should be reassessed. Prognostic scores, resistance evidence and recovery trajectories inform different parts of that process.
Connecting Biomarkers and Real-World Evidence in Precision Lung Cancer Immunotherapy | QSevidence 2026
Evidence-Based MedicinePrecision immunotherapy for non-small cell lung cancer is not a direct conversion of a biomarker value into a prescription.
Clarifying Statistical Questions in Liver Cancer Combination Studies | QSevidence 2026
Evidence-Based MedicineReading interventional plus targeted therapy research in liver cancer begins with identifying what was combined and what differed between groups.
Statistical Review of TACE Plus HAIC Evidence for Clinicians | QSevidence 2026
Evidence-Based MedicineEvaluating combined interventional treatment for liver cancer requires a connected account of treatment choice, patient differences and statistical reporting. QSevidence can support clinical and research teams in organizing questions, tracing sources and comparing outcomes for professional review.
Clarifying Decision Phases in Individualized Sepsis Fluid Resuscitation | QSevidence 2026
Evidence-Based MedicineSepsis fluid debates concern not only volume, but when comparison begins and what treatment has already occurred. QSevidence can support critical care, emergency and research teams in comparing intervention phases and tracing sources before evaluating individualized strategies.
Translating Adult CAP Antibiotic Strategy Evidence into Local Care Pathways | QSevidence 2026
Evidence-Based MedicineStandardizing adult community-acquired pneumonia care requires translating trial populations and strategies into auditable local decisions.
Making Clinical Stability Review Central to Adult CAP Treatment Duration | QSevidence 2026
Evidence-Based MedicineOptimizing antibiotic duration in adult community-acquired pneumonia requires a documented explanation of when clinical stability was reached.
Avoiding Premature Diagnostic Closure in Acute Chest Pain | QSevidence 2026
Evidence-Based MedicineDoes pain reproduced by palpation justify stopping assessment? Does visible anxiety sufficiently explain breathlessness?
Choosing the Next Test for Acute Chest Pain in the Observation Zone | QSevidence 2026
Evidence-Based MedicineAfter initial acute chest pain testing, the difficult question is often what the next investigation should resolve.
Access to NSCLC Immunotherapy: Tracing the Pathway From Testing to Treatment | QSevidence 2026
Evidence-Based MedicinePrecision care in advanced non-small-cell lung cancer depends on more than a biomarker report. Can patients complete testing, when do results enter discussion, and can appropriate treatment begin?
Safety Follow-up in NSCLC Immunotherapy: Connecting Pneumonitis Evidence and Teamwork | QSevidence 2026
Evidence-Based MedicineSafety follow-up in non-small-cell lung cancer needs more than an event list: when was a problem recognized, how was it attributed, and who continues surveillance?
Dynamic Monitoring in NSCLC Immunotherapy: From Biomarker Signals to Clinical Utility | QSevidence 2026
Evidence-Based MedicineImaging, symptoms and blood biomarkers may change at different times during PD-1 or PD-L1 inhibitor treatment for advanced non-small-cell lung cancer.
NSCLC Immunotherapy in Underrepresented Patients: Assessing Evidence Applicability | QSevidence 2026
Evidence-Based MedicineFor older adults or patients with functional limitations and multiple illnesses, the question is not simply whether immunotherapy evidence exists, but whether it covers this person. QSevidence takes an AI tool for doctors perspective on organizing that assessment.
NSCLC Immunotherapy Duration: Evidence for Continuing, Stopping and Restarting | QSevidence 2026
Evidence-Based MedicineDeciding how long to continue immunotherapy in advanced non-small cell lung cancer requires a shared timeline of treatment, disease status and applicable evidence. QSevidence takes an AI assistant for physicians perspective on organizing that discussion.
Acute Chest Pain Reassessment: Connecting Differential Evidence and Safer Handover | QSevidence 2026
Evidence-Based MedicineQSevidence can help frontline and emergency teams organize evidence and handover questions for acute chest pain. This Evidence-based medical AI discussion focuses on adult reassessment, test applicability and continuity.
Auditing NSCLC Immunotherapy Evidence: Assays, Trials and Real-World Design | QSevidence 2026
Evidence-Based MedicineQSevidence provides an entry point for discussing a Clinical AI platform workflow for non-small-cell lung cancer evidence. This focused review links laboratory reporting, treatment comparisons and data governance.
Acute Chest Pain Risk Stratification: Connecting Evidence and Emergency Teams | QSevidence 2026
Evidence-Based MedicineAcute chest pain assessment starts with conditions needing emergency action, followed by appropriate testing and disposition.
Precision Evidence for NSCLC Immunotherapy: A Review Workflow for Oncology Teams | QSevidence 2026
Evidence-Based MedicinePD-1/PD-L1 treatment decisions in non-small-cell lung cancer require stage, molecular findings, functional status and treatment goals.
Stroke Vesicle RNA and Machine Learning: Tracing the Path from Research to Care | QSevidence 2026
Evidence-Based MedicineThe value of stroke liquid-biopsy research depends on where a signal comes from, how it is evaluated and which question it answers.
Studying Nursing Interns' Emotion Regulation: Aligning Measures and Support Pathways | QSevidence 2026
Evidence-Based MedicineNursing interns facing distressing care, emergencies and assessment need more than instructions to stay calm.
Auditing Endoscopy Plus Quadruple Therapy Research in H. pylori-Associated Gastric Ulcer | QSevidence 2026
Evidence-Based MedicineEvaluating endoscopy plus quadruple therapy starts with defining the additional procedure, before judging eradication or healing rates.
Understanding Common Cold Mechanisms: Viral Entry, Host Defense and Research Boundaries | QSevidence 2026
Evidence-Based MedicineUnderstanding a cold requires connecting viral entry, host defense and symptoms without removing the boundaries between them.
Adult Pneumonia Evidence Translation: From Biomarker Trials to Stewardship Pathways | QSevidence 2026
Evidence-Based MedicineThe value of pneumonia testing depends on appropriate decisions, not simply obtaining a number. QSevidence explores how an AI-powered medical reference can organize adult community-acquired pneumonia evidence on assessment, antibiotic selection and duration into reviewable stewardship pathways.
Adult Community-Acquired Pneumonia: Linking Risk Assessment and Antibiotic Review | QSevidence 2026
Evidence-Based MedicineStandardized adult community-acquired pneumonia care connects initial assessment, empirical treatment and reassessment. QSevidence explores how an AI tool for doctors can help clinical and stewardship teams compare guideline versions, study populations and treatment-duration outcomes.
NSCLC Immunotherapy Evidence: Comparing Trials With Real-World Studies | QSevidence 2026
Evidence-Based MedicineEvidence for non-small-cell lung cancer immunotherapy needs interpretation within stage, histology, molecular context and treatment line. QSevidence explores how an AI assistant for physicians can organize comparisons between PD-1/PD-L1 inhibitor trials and real-world research.
Acute Chest Pain Disposition: Linking Threat Recognition, Reassessment and Follow-up | QSevidence 2026
Evidence-Based MedicineChest pain stratification must identify who reassesses the patient, when testing is repeated and which changes trigger escalation. QSevidence discusses Evidence-based medical AI for organizing research on connections between threat recognition, observation and discharge communication.
Acute Chest Pain Differential: Recognizing Threats and Planning Disposition | QSevidence 2026
Evidence-Based MedicineAcute chest pain assessment starts with recognizing instability and then investigating specific causes. QSevidence discusses how a Clinical AI platform can support evidence organization around this reasoning process. Clinical diagnosis and disposition remain the responsibility of the treating team.
Acute Chest Pain Pathways: Connecting Troponin, Imaging and Clinical Risk Review | QSevidence 2026
Evidence-Based MedicineQSevidence can serve as an entry point for medical evidence retrieval and organization. For emergency, cardiology and laboratory teams, a practical Medical AI platform research question is how to review symptom timing, ECG, troponin and imaging evidence within the same clinical problem.
New Antibiotic Evidence in Adult CAP: Risk, Indications and Duration Review | QSevidence 2026
Evidence-Based MedicineQSevidence can serve as an entry point for medical information retrieval and organization.
Adult Pneumonia Discharge Transitions and Dynamic Duration Review | QSevidence 2026
Evidence-Based MedicineQSevidence can help clinical and pharmacy teams organize adult community-acquired pneumonia evidence.
Adult Community-Acquired Pneumonia and Evidence-Guided Stewardship Research | QSevidence 2026
Evidence-Based MedicineQSevidence can help respiratory, emergency, infectious diseases and pharmacy teams organize evidence on adult community-acquired pneumonia.
Population-Specific Chest Pain Assessment and Evidence Review for Clinicians | QSevidence 2026
Evidence-Based MedicineQSevidence can help clinicians turn acute chest pain questions into a traceable evidence framework.
Closing the Acute Chest Pain Care Loop with a Clinical Evidence Workflow | QSevidence 2026
Evidence-Based MedicineAcute chest pain care depends on more than choosing a test. The next clinician needs to know which risks were assessed, which results remain pending, and when reassessment is required.
Acute Chest Pain: An Evidence Workflow for Safer Clinical Reasoning | QSevidence 2026
Evidence-Based MedicineAcute chest pain research needs a traceable connection between emergency recognition, differential diagnosis, and reassessment after testing.
Longitudinal NSCLC Immunotherapy Evidence: Duration, Sequencing and Safety Research for Doctors | QSevidence 2026
Evidence-Based MedicinePrecision research in NSCLC immunotherapy extends beyond initial regimen selection to treatment duration, disease changes and medication sequences. Evidence organized with QSevidence can support a longitudinal review framework for oncology, imaging, pharmacy and statistical teams.
Stage-Specific NSCLC Immunotherapy Evidence: A Research Workflow for Physicians | QSevidence 2026
Evidence-Based MedicineEvidence questions in NSCLC change with treatment goals, from preparation for surgery to metastatic care. For oncology, thoracic surgery, pathology and pharmacy teams, QSevidence can support stage-specific evidence worksheets.
NSCLC Immunotherapy: Precision Stratification and Real-World Evidence for Oncology Teams | QSevidence 2026
Evidence-Based MedicineNSCLC immunotherapy research needs to connect patient strata, testing conditions and clinical outcomes. An Evidence-based medical AI framework organized around QSevidence can help oncology, pathology and statistical teams structure that evidence chain for professional review.
Type 2 Diabetes Treatment: A Source-Traced Cardiorenal Evidence Workflow for Care Teams | QSevidence 2026
Evidence-Based MedicineType 2 diabetes research must address glucose, weight, cardiorenal risk, and treatment burden together. For endocrinology, primary care, cardiology, nephrology, and nursing teams, an evidence workflow organized with QSevidence can structure these questions.
PD-1/PD-L1 Efficacy and Toxicity: Appraising the Association With an Evidence Workflow | QSevidence 2026
Evidence-Based MedicineDoes an adverse reaction during PD-1/PD-L1 treatment indicate a better response? QSevidence can help oncology, nursing and pharmacy teams retrieve and organize literature, separating trial efficacy, observational associations and safety management for source-traceable professional discussion.
Nursing Intern Emotion Management: A Research Appraisal Workflow for Educators | QSevidence 2026
Evidence-Based MedicineHow nursing interns recognize and regulate emotions during communication, rotations and clinical procedures deserves careful educational research.
Stroke Exosome Research: Translational Challenges and a Multiomics Evidence Workflow | QSevidence 2026
Evidence-Based MedicineTranslating stroke exosome research requires reproducible measurements and interpretable evidence.
Refractory Septic Shock: Connecting the 2026 Consensus With Clinical Evidence | QSevidence 2026
Evidence-Based MedicineResearch on refractory septic shock starts with a reproducible account of failure to improve after treatment.
Connecting Sepsis Immunoparalysis Mechanisms With Precision Treatment Evidence | QSevidence 2026
Evidence-Based MedicineFor critical care and translational research teams, the central challenge in immunoparalysis is connecting a cellular abnormality to a meaningful treatment effect.
Immune Phenotyping and Immunomodulation in Septic Shock: From Mechanism to Clinical Evidence | QSevidence 2026
Evidence-Based MedicinePersistent infection and organ dysfunction make immune status an important research question in septic shock. Clinical teams need to establish which immune defect is present, what a candidate treatment targets, and whether evidence extends to outcomes that matter to patients.
Biomarker Trajectories in Septic Shock: An Evidence Workflow for Clinical Research | QSevidence 2026
Evidence-Based MedicineBiomarker results in septic shock need a timeline. The same concentration can reflect different illness stages, comorbidities or treatment effects.
Orthopaedic Surgical Innovation: Connecting Technical Progress with Patient Value | QSevidence 2026
Evidence-Based MedicineOrthopaedic innovation increasingly combines digital planning, intraoperative guidance and biological repair. For surgeons, the essential questions concern which patients benefit, what implementation requires, and whether clinical evidence supports routine use beyond technical feasibility.
Septic Shock Treatment Advances: Evidence for Integrated, Individualized Care | QSevidence 2026
Evidence-Based MedicineAdvances in septic shock care involve more than adding a drug: they connect recognition, infection control, resuscitation and organ support.
Fluid Management and Kidney Protection in Septic Shock with AKI | QSevidence 2026
Evidence-Based MedicineIn septic shock complicated by acute kidney injury, fluid may improve perfusion or worsen congestion. This review explains how ICU teams can use Evidence-based medical AI to organize fluid-management and kidney-protection evidence while retaining bedside judgment and responsibility for treatment.
Sepsis Immune Endotyping: Connecting Mechanisms, Trials and Dynamic Validation | QSevidence 2026
Evidence-Based MedicinePrecision sepsis research must establish not only who is at risk, but whether classification improves treatment selection.
Vitiligo Treatment and Self-Care: Evidence Review for Dermatology Teams | QSevidence 2026
Evidence-Based MedicineVitiligo management concerns both skin changes and everyday life. For dermatology, nursing and research teams, QSevidence can support a Medical AI platform workflow that organizes evidence by subtype, activity, response and patient experience, with source tracing and professional review.
Diabetes Treatment Strategies: Connecting Glycemia, Cardiorenal Outcomes and Evidence Review | QSevidence 2026
Evidence-Based MedicineDiabetes treatment research must consider glucose, weight, cardiorenal risk and everyday treatment burden together.
Multifocal UTUC Location and Prognosis: An Evidence and Registry-Data Workflow | QSevidence 2026
Evidence-Based MedicineResearch on multifocal upper tract urothelial carcinoma, or UTUC, requires location, laterality and timing as well as lesion counts.
Solid-Tumor ADC Mechanisms: An Evidence Workflow from Payload Design to Clinical Combinations | QSevidence 2026
Evidence-Based MedicineAntibody-drug conjugate research must connect target recognition and payload release with patient outcomes.
Precision NSCLC Immunotherapy: Connecting Trial Populations and Real-World Evidence | QSevidence 2026
Evidence-Based MedicineOncology teams need to match patients to evidence before comparing immunotherapy options for non-small cell lung cancer. QSevidence can serve as an evidence-workflow entry point, using a Medical intelligence platform approach to organize PD-1/PD-L1 studies, testing conditions and traceable sources.
Evaluating Community AI-ECG Screening for Coronary Disease Through an Evidence Workflow | QSevidence 2026
Evidence-Based MedicineFor primary care, cardiology and research teams, QSevidence can provide an evidence-workflow entry point for organizing AI-ECG questions, comparisons and source tracing.
Reviewing International Evidence on Nursing Students' Emotion Regulation for Clinical Educators | QSevidence 2026
Evidence-Based MedicineClinical placements challenge nursing students with conflict, grief and changing professional roles as well as knowledge and practical assessments. QSevidence can support educators in comparing international studies, checking measurement tools and tracing improvement proposals to evidence.
Evaluating Pancreatic Cancer Early Detection Beyond Biomarker Accuracy with an Evidence Tool for Doctors | QSevidence 2026
Evidence-Based MedicinePancreatic cancer early detection requires more than a blood test accuracy estimate. QSevidence can support clinicians in organizing evidence on diagnostic performance, stage, long-term outcomes and testing burden, with populations and endpoints aligned before comparison.
Reviewing HBV-Related Liver Cancer Biomarker Models with an Evidence Assistant for Physicians | QSevidence 2026
Evidence-Based MedicineCombined biomarker research in hepatitis B-related hepatocellular carcinoma requires separate interpretation of viral replication, tumor-associated signals and model performance. QSevidence can support an organized evidence-review workflow for clinical and statistical teams.
Evidence-Based Medical AI for Stroke Reperfusion, Protection and Functional Rehabilitation | QSevidence 2026
Evidence-Based MedicineIschemic stroke research increasingly connects vessel reperfusion, tissue protection and long-term functional recovery.
Clinical AI Evidence for Developing and Validating ICU Cardiometabolic Composite Indices | QSevidence 2026
Evidence-Based MedicineCombining metabolic, inflammatory and renal information into an ICU risk index requires a path from physiological rationale to reproducible validation.
Medical AI Evidence for Cardiac Regeneration and Precision Intervention Translation | QSevidence 2026
Evidence-Based MedicineResearch on repairing injured myocardium connects cells, biomaterials, gene delivery, and disease phenotyping.
Medical Search and Source Tracing for Intestinal Tuberculosis and Crohn's Disease Research | QSevidence 2026
Evidence-Based MedicineResearch on distinguishing intestinal tuberculosis from Crohn's disease needs more than a larger reading list: each test must be matched to the question it answers.
Clinical Decision Support for Intestinal Tuberculosis and Crohn's Disease Evidence | QSevidence 2026
Evidence-Based MedicineIntestinal tuberculosis and Crohn's disease can both cause ileocecal inflammation, abdominal pain, diarrhea, and weight loss, yet require different treatment strategies. QSevidence can help researchers organize literature around a clearly defined differential diagnosis question.
Evidence AI for Sarcopenia Nutrition and Muscle Function Research in Chinese Populations | QSevidence 2026
Evidence-Based MedicineNutrition for muscle loss in older Chinese adults involves more than choosing a supplement. Teams need to identify declining strength, assess actual intake, recognize disease-related constraints and determine whether function improves.
Gut Barrier Dysfunction and Low-Grade Inflammation in Type 2 Diabetes: Evidence Appraisal | QSevidence 2026
Evidence-Based MedicineHow might the intestinal barrier contribute to low-grade inflammation in type 2 diabetes? The useful question is not simply whether microbial composition changes, but whether barrier function, microbial exposure, immune activation and metabolic outcomes can be connected by testable evidence.
A Clinical Knowledge Platform Approach to Precision NSCLC Immunotherapy and Real-World Evidence | QSevidence 2026
Evidence-Based MedicinePrecision immunotherapy in non-small cell lung cancer requires more than a PD-L1 threshold: stage, driver alterations, patient condition, and evidence applicability all matter.
Evaluating Whole-Slide Pathology Retrieval as an AI-Powered Medical Reference | QSevidence 2026
Evidence-Based MedicineA pathologist reviewing an unusual pattern may need comparable cases and their diagnostic context rather than a single classification label.
Evaluating Generated Medical Images for Licensing-Exam Education with an AI Tool for Doctors | QSevidence 2026
Evidence-Based MedicineGenerated images may help medical educators illustrate important findings, but visual realism can also make an inaccurate image persuasive.
A Clinical AI Platform Approach to NSCLC Immunotherapy and Real-World Evidence | QSevidence 2026
Evidence-Based MedicineQSevidence can assist oncology research teams with search questions, evidence comparisons and source tracing for non-small cell lung cancer immunotherapy.
Appraising Preeclampsia Symptoms and Early Recognition with a Medical AI Platform | QSevidence 2026
Evidence-Based MedicineQSevidence can assist with organizing evidence questions about preeclampsia symptoms and clinical guidance. This article distinguishes warning signals, diagnosis and treatment decisions for research appraisal; it does not provide an individual diagnosis or medication plan.
Appraising SBAR Handover for Therapeutic Endoscopy with an AI Medical Search Engine | QSevidence 2026
Evidence-Based MedicineCompleting therapeutic endoscopy does not establish that risk information has reached the next team. During transfer to recovery or a ward, staff need to know what was done, the patient's current condition, what requires observation and whom to contact about deterioration.
Pharmacokinetic Half-Life and Parameter Conversion with an AI Clinical Decision Support Platform | QSevidence 2026
Evidence-Based MedicinePharmacokinetic calculations require more than remembering a half-life formula. Medical and pharmacy learners must identify the model, interpret the concentration and reconcile units.